- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06331156
A Study on the Immune Response and Safety of Inactivated Poliovirus Vaccine (IPV) When Co-administered With Human Rotavirus (HRV) Porcine Circovirus (PCV)-Free Vaccine in Healthy Chinese Infants
A Phase III, Open-label, Randomized, Controlled Study to Evaluate the Immunogenicity and Safety of Inactivated Poliovirus Vaccine (IPV) When Co-administered With Porcine Circovirus (PCV)-Free Liquid Formulation of an Oral Live Attenuated Human Rotavirus (HRV) Vaccine in Healthy Chinese Infants
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Estimated)
Phase
- Phase 3
Contacts and Locations
Study Contact
- Name: US GSK Clinical Trials Call Center
- Phone Number: 877-379-3718
- Email: GSKClinicalSupportHD@gsk.com
Study Contact Backup
- Name: EU GSK Clinical Trials Call Center
- Phone Number: +44 (0) 20 89904466
- Email: GSKClinicalSupportHD@gsk.com
Study Locations
-
-
-
Wenshan, China, 663100
- Recruiting
- GSK Investigational Site
-
Principal Investigator:
- Xiaoqing Liu
-
Contact:
- US GSK Clinical Trials Call Center
- Phone Number: 877-379-3718
- Email: GSKClinicalSupportHD@gsk.com
-
Contact:
- EU GSK Clinical Trials Call Centre
- Phone Number: +44 (0) 20 8990 4466
- Email: GSKClinicalSupportHD@gsk.com
-
-
Sichuan
-
Chengdu, Sichuan, China, 610041
- Recruiting
- GSK Investigational Site
-
Contact:
- US GSK Clinical Trials Call Center
- Phone Number: 877-379-3718
- Email: GSKClinicalSupportHD@gsk.com
-
Contact:
- EU GSK Clinical Trials Call Centre
- Phone Number: +44 (0) 20 8990 4466
- Email: GSKClinicalSupportHD@gsk.com
-
Principal Investigator:
- Xuecheng Liu
-
Guang'an, Sichuan, China, 638300
- Recruiting
- GSK Investigational Site
-
Contact:
- US GSK Clinical Trials Call Center
- Phone Number: 877-379-3718
- Email: GSKClinicalSupportHD@gsk.com
-
Contact:
- EU GSK Clinical Trials Call Centre
- Phone Number: +44 (0) 20 8990 4466
- Email: GSKClinicalSupportHD@gsk.com
-
Principal Investigator:
- Xuecheng Liu
-
Neijiang, Sichuan, China, 641200
- Recruiting
- GSK Investigational Site
-
Contact:
- US GSK Clinical Trials Call Center
- Phone Number: 877-379-3718
- Email: GSKClinicalSupportHD@gsk.com
-
Contact:
- EU GSK Clinical Trials Call Centre
- Phone Number: +44 (0) 20 8990 4466
- Email: GSKClinicalSupportHD@gsk.com
-
Principal Investigator:
- Yulin Jing
-
-
Yunnan
-
Wenshan, Yunnan, China, 663300
- Recruiting
- GSK Investigational Site
-
Contact:
- US GSK Clinical Trials Call Center
- Phone Number: 877-379-3718
- Email: GSKClinicalSupportHD@gsk.com
-
Contact:
- EU GSK Clinical Trials Call Centre
- Phone Number: +44 (0) 20 8990 4466
- Email: GSKClinicalSupportHD@gsk.com
-
Principal Investigator:
- Xiaoqiang Liu
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Child
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Participants' parent(s)/Legally Acceptable Representative(s) [LAR(s)], who, in the opinion of the investigator, can and will comply with the requirements of the protocol.
- Written or witnessed/thumb printed informed consent obtained from the parent(s)/LAR(s) of the participant prior to performance of any study specific procedure.
- Healthy participants as established by medical history and clinical examination before entering into the study.
- A male or female of Chinese origin, between and including, 6 and 10 weeks (42-76 days) of age at the time of study enrolment.
- Born after a gestation period of 36 to 42 weeks inclusive.
Exclusion Criteria:
Medical conditions
- History of any reaction or hypersensitivity likely to be exacerbated by any component of the study interventions.
- Any confirmed or suspected immunosuppressive or immunodeficient condition, based on medical history and physical examination (no laboratory testing required).
- Hypersensitivity to latex.
- History of severe combined immunodeficiency.
- History of seizures or progressive neurological disease.
- Family history of congenital or hereditary immunodeficiency.
- Uncorrected congenital malformation of the gastrointestinal tract that would predispose for intussusception (IS).
- History of IS.
- Major congenital defects, or serious chronic illness as assessed by the investigator.
- Any contraindications to IPV.
- Previous confirmed occurrence of rotavirus gastroenteritis (RVGE).
- History of poliomyelitis.
- Participants with confirmed or suspected Coronavirus Disease 2019 (COVID-19).
Prior/Concomitant therapy
- Use of any investigational or non-registered product other than the study interventions during the period beginning 30 days before the first dose of study interventions (Day -29 to Day 1), or planned use during the study period.
Planned administration/administration of a vaccine not foreseen by the study protocol in the period starting 30 days before the first dose and ending 30 days after the last dose of study interventions administration*, with the exception of the inactivated influenza vaccine, which is allowed at any time during the study and other licensed routine childhood vaccinations.
*In case emergency mass vaccination for an unforeseen public health threat (e.g., a pandemic) is recommended and/or organized by public health authorities outside the routine immunization program, the time period described above can be reduced if, necessary for that vaccine, provided it is used according to the local governmental recommendations and that the Sponsor is notified accordingly.
- Administration of long-acting immune-modifying drugs from birth or planned administration at any time during the study period.
- Administration of immunoglobulins and/or any blood products or plasma derivatives from birth or planned administration during the study period.
- Chronic administration of immunosuppressants or other immune-modifying drugs since birth. For corticosteroids, this will mean prednisone >=0.5 milligram/kilogram (kg)/day, or equivalent. Inhaled, intra-articular and topical steroids are allowed.
- Previous vaccination against RV.
- Previous vaccination against poliomyelitis.
Prior/Concurrent clinical study experience
- Concurrently participating in another clinical study, at any time during the study period, in which the participant has been or will be exposed to an investigational or a non-investigational intervention.
Other exclusions
- Child in care.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Co-administration Group
Participants receive 2 doses of HRV PCV-free vaccine co-administered with the first 2 doses of IPV vaccine at Month 0.5 and Month 1.5, followed by the third dose of IPV vaccine administered at Month 2.5.
|
2 doses of HRV PCV-free vaccine are administered orally at Month 0.5 and Month 1.5 (Co-administration Group) and at Day 1 and Month 1 (Staggered Group), according to the immunization schedule for HRV vaccine licensed outside of China.
PCV-free implies no detection of PCV-1 and PCV-2 according to the limit of detection of the tests used.
Other Names:
3 doses of IPV vaccine are administered intramuscularly at Month 0.5, Month 1.5 and Month 2.5 (Co-administration Group and Staggered Group), according to the recommended schedule for vaccination against poliovirus in China.
Other Names:
|
Active Comparator: Staggered Group
Participants receive 2 doses of HRV PCV-free vaccine administered at Day 1 and Month 1, and 3 doses of IPV vaccine administered at Month 0.5, Month 1.5, and Month 2.5.
|
2 doses of HRV PCV-free vaccine are administered orally at Month 0.5 and Month 1.5 (Co-administration Group) and at Day 1 and Month 1 (Staggered Group), according to the immunization schedule for HRV vaccine licensed outside of China.
PCV-free implies no detection of PCV-1 and PCV-2 according to the limit of detection of the tests used.
Other Names:
3 doses of IPV vaccine are administered intramuscularly at Month 0.5, Month 1.5 and Month 2.5 (Co-administration Group and Staggered Group), according to the recommended schedule for vaccination against poliovirus in China.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Percentage of participants with seroconversion for anti-poliovirus types 1, 2 and 3 neutralizing antibody (Ab)
Time Frame: At 1 month post-Dose 3 of IPV (Month 3.5)
|
Seroconversion for anti-poliovirus types 1, 2 and 3 neutralizing Ab is defined as: - Ab titer greater than or equal to (>=) 1:8 at 1 month after the 3 dose primary vaccination schedule of IPV in participants with Ab titer lower than (<) 1:8 at pre-vaccination, - >= 4-fold increase in Ab titer at 1 month after the 3 dose primary vaccination schedule of IPV in participants with Ab titer >= 1:8 at pre-vaccination. |
At 1 month post-Dose 3 of IPV (Month 3.5)
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Anti-poliovirus types 1, 2 and 3 neutralizing Ab geometric mean titers (GMTs)
Time Frame: At 1 month post-Dose 3 of IPV (Month 3.5)
|
At 1 month post-Dose 3 of IPV (Month 3.5)
|
|
Percentage of participants with anti-poliovirus types 1, 2 and 3 neutralizing Ab titers >=1:8 and >=1:64
Time Frame: At 1 month post-Dose 3 of IPV (Month 3.5)
|
At 1 month post-Dose 3 of IPV (Month 3.5)
|
|
Percentage of participants with seroconversion for anti-rotavirus (RV) immunoglobulin A (IgA) Ab
Time Frame: At 1 month post-Dose 2 of HRV PCV-free (Month 2 for Staggered Group and Month 2.5 for Co-administration Group)
|
Seroconversion for anti-RV IgA Ab is defined as: anti-RV IgA Ab concentration >= 20 unit per milliliter (U/mL) at 1 month post-Dose 2 of HRV PCV-free vaccine, in participants who were initially seronegative (i.e., with anti-RV IgA Ab concentration < 20 U/mL prior to the first dose of HRV PCV-free vaccine).
|
At 1 month post-Dose 2 of HRV PCV-free (Month 2 for Staggered Group and Month 2.5 for Co-administration Group)
|
Anti-RV IgA Ab geometric mean concentrations (GMCs)
Time Frame: At 1 month post-Dose 2 of HRV PCV-free (Month 2 for Staggered Group and Month 2.5 for Co-administration Group)
|
At 1 month post-Dose 2 of HRV PCV-free (Month 2 for Staggered Group and Month 2.5 for Co-administration Group)
|
|
Percentage of participants with anti-RV IgA Ab concentrations >= 90 U/mL
Time Frame: At 1 month post-Dose 2 of HRV PCV-free (Month 2 for Staggered Group and Month 2.5 for Co-administration Group)
|
At 1 month post-Dose 2 of HRV PCV-free (Month 2 for Staggered Group and Month 2.5 for Co-administration Group)
|
|
Percentage of participants reporting solicited systemic events
Time Frame: Within 14 days after Dose 1 and Dose 2 of HRV PCV-free and IPV (Dose 1&2 administered at Day 1 & Month 1 (HRV PCV-free) and at Month 0.5 & Month 1.5 (IPV) for Staggered Group and at Month 0.5 & Month 1.5 (HRV PCV-free & IPV) for Co-administration Group)
|
Solicited systemic events include fever, diarrhea, vomiting, irritability/fussiness, loss of appetite, cough/runny nose.
Fever is defined as body temperature >= 37.5 degrees Celsius (°C) and the preferred location for measuring temperature is the axilla.
|
Within 14 days after Dose 1 and Dose 2 of HRV PCV-free and IPV (Dose 1&2 administered at Day 1 & Month 1 (HRV PCV-free) and at Month 0.5 & Month 1.5 (IPV) for Staggered Group and at Month 0.5 & Month 1.5 (HRV PCV-free & IPV) for Co-administration Group)
|
Percentage of participants reporting unsolicited adverse events (AEs)
Time Frame: Within 31 days after each dose of HRV PCV-free (HRV PCV-free administered at Day 1 and Month 1 for Staggered Group and at Month 0.5 and Month 1.5 for Co-administration group)
|
Unsolicited AEs include any AE reported in addition to those solicited during the clinical study.
|
Within 31 days after each dose of HRV PCV-free (HRV PCV-free administered at Day 1 and Month 1 for Staggered Group and at Month 0.5 and Month 1.5 for Co-administration group)
|
Percentage of participants reporting serious adverse events (SAEs)
Time Frame: From the first dose of the study intervention (Day 1 for Staggered group and Month 0.5 for Co-administration group) up to study end (Month 3.5)
|
An SAE is any untoward medical occurrence that results in death, is life-threatening, requires hospitalization or prolongation of existing hospitalization or results in disability/incapacity or in other situations that are considered serious per medical or scientific judgment.
|
From the first dose of the study intervention (Day 1 for Staggered group and Month 0.5 for Co-administration group) up to study end (Month 3.5)
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 218485
- 2022-000708-36 (EudraCT Number)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
IPD Sharing Time Frame
IPD Sharing Access Criteria
IPD Sharing Supporting Information Type
- STUDY_PROTOCOL
- SAP
- ICF
- CSR
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Gastroenteritis
-
GlaxoSmithKlineCompletedRotavirus Gastroenteritis | Nosocomial Rotavirus Gastroenteritis
-
National Institute of Allergy and Infectious Diseases...Completed
-
Merck Sharp & Dohme LLCCompletedRotavirus Gastroenteritis
-
VaxartCompletedNorovirus GastroenteritisUnited States
-
VaxartCompletedNorovirus GastroenteritisUnited States
-
National Institute of Allergy and Infectious Diseases...WithdrawnGastroenteritis NorovirusUnited States
-
Merck Sharp & Dohme LLCCompletedRotavirus Gastroenteritis
-
Christian Medical College, Vellore, IndiaKarolinska InstitutetCompletedRotavirus GastroenteritisIndia
-
GlaxoSmithKlineCompletedRotavirus GastroenteritisBrazil
Clinical Trials on HRV PCV-free
-
GlaxoSmithKlineCompletedInfections, Rotavirus | Rotavirus VaccinesUnited States, Finland, Germany, Taiwan, Spain, Costa Rica, Korea, Republic of, Japan
-
GlaxoSmithKlineCompletedInfections, RotavirusUnited States, Taiwan, Canada, Hong Kong, Turkey
-
GlaxoSmithKlineCompleted
-
Nagasaki UniversityLondon School of Hygiene and Tropical Medicine; National Institute of Hygiene... and other collaboratorsCompleted
-
Brazilian Institute of Higher Education of CensaCompletedVentilator Associated Pneumonia | Infections, RespiratoryBrazil
-
University Hospital, Clermont-FerrandClinique cardio-pneumologique de Durtol; AlmerysCompletedMyocardial Infarction | Cardiac RehabilitationFrance
-
Centocor Ortho Biotech Services, L.L.C.Completed
-
Imam Abdulrahman Bin Faisal UniversityCompletedLung DiseasesSaudi Arabia
-
Huashan HospitalUnknownMechanical Ventilation | Bariatric SurgeryChina